NASDAQ$ARQT
Arcutis Biotherapeutics Inc · Q2 2021 earnings
Q2 2021 earnings · · Investor relations
Briefing
Arcutis reported financial results for the second quarter of 2021 and provided a business update.
Arcutis Biotherapeutics reported a net loss of $42.0 million for the quarter ended June 30, 2021. The company's cash, cash equivalents, and marketable securities totaled $410.9 million as of June 30, 2021, which is expected to fund operations well into 2023. The company is on track to submit NDA and initiated Phase 3 trials.
- Anticipates submission of an NDA for topical roflumilast cream as a potential treatment for plaque psoriasis late in the third quarter or early in the fourth quarter of 2021.
- Initiated single pivotal Phase 3 trial of topical roflumilast foam in seborrheic dermatitis.
- Anticipates initiation of single pivotal Phase 3 trial of topical roflumilast foam in scalp psoriasis in Q3 2021.
- Enrolling pivotal Phase 3 trials of topical roflumilast cream in atopic dermatitis.
Headline financials
Revenue & EPS history
Arcutis · Revenue · Quarterly
$0
Forward guidance
Arcutis believes that its current cash, cash equivalents, and marketable securities will be sufficient to fund its operations well into 2023. Anticipates multiple top-line readouts in 2022.
Tailwinds
- NDA submission for plaque psoriasis on track.
- Initiation of Phase 3 program of topical roflumilast.
- Multiple top-line readouts in 2022 expected.
- Strong financial position allows building key capabilities.
- Positions well for an exciting next 18 months.
Headwinds
- Phase 2 study of ARQ-252 in chronic hand eczema did not meet its primary endpoint.
- Analyses of the study pointed toward inadequate local drug delivery to the skin as a key driver of the lack of efficacy.
- Company announced the termination of the Phase 2a clinical trial evaluating ARQ-252 as a potential treatment for vitiligo, based on the aforementioned analyses of the Phase 2 chronic hand eczema study.
- Reformulation efforts are continuing.
- Risks inherent in the clinical development process and regulatory approval process.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 20 quarterly earnings reports · overlaid with Q2 2021
+1.8%
Avg return
Earnings day
+1.1%
Avg return
5 days after
-0.5%
Avg return
30 days after
64%
16 / 25 earnings
Positive
+27.2%
Q3 2025
Best reaction
-15.6%
Q1 2023
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q1 2026 | +3.2% | -9.3% | -9.4% | |
| Q4 2025 | +5.7% | -12.6% | -21.4% | |
| Q3 2025 | +27.2% | +28.9% | +57.6% | |
| Q1 2025 | -4.6% | +0.5% | +0.3% | |
| Q4 2024 | +8.4% | +5.2% | +28.9% | |
| Q3 2024 | +11.8% | +16.6% | +33.3% | |
| Q2 2024 | -14.6% | -13.1% | +7.1% | |
| Q1 2024 | +15.6% | +15.1% | +16.9% | |
| Q4 2023 | +7.4% | +21.5% | +2.3% | |
| Q3 2023 | +5.4% | -0.9% | -10.4% | |
| Q2 2023 | -2.0% | -6.5% | -21.0% | |
| Q1 2023 | -15.6% | -29.3% | -29.8% | |
| Q4 2022 | +4.4% | -2.7% | -31.8% | |
| Q3 2022 | +0.6% | +3.1% | -8.4% | |
| Q2 2022 | +13.2% | +11.8% | +8.6% | |
| Q1 2022 | -11.8% | -14.1% | -3.5% | |
| Q4 2021 | +1.1% | +12.6% | +10.7% | |
| Q3 2021 | -7.5% | -6.9% | -35.6% | |
| Q2 2021 | +3.1% | +5.2% | +4.1% | |
| Q1 2021 | -3.4% | -1.8% | -23.1% | |
| Q4 2020 | -0.1% | +3.6% | -10.5% | |
| Q3 2020 | -3.8% | +8.9% | +37.1% | |
| Q2 2020 | +1.7% | +1.8% | -6.5% | |
| Q1 2020 | +0.0% | -4.6% | -4.6% | |
| Q4 2019 | +0.0% | -4.6% | -4.6% | |
| Q3 2019 | — | — | — | |
| Q2 2019 | — | — | — | |
| Q1 2019 | — | — | — | |
| Q4 2018 | — | — | — | |
| Q3 2018 | — | — | — | |
| Q2 2018 | — | — | — | |
| Q1 2018 | — | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro